- Home
- ARVN vs BEAM Comparison
ARVN vs BEAM Comparison
Compare ARVN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- BEAM
- Stock Information
- Founded
- ARVN 2015
- BEAM 2017
- Country
- ARVN United States
- BEAM United States
- Employees
- ARVN N/A
- BEAM N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARVN Health Care
- BEAM Health Care
- Exchange
- ARVN Nasdaq
- BEAM Nasdaq
- Market Cap
- ARVN 1.7B
- BEAM 1.9B
- IPO Year
- ARVN 2018
- BEAM 2020
- Fundamental
- Price
- ARVN $25.11
- BEAM $23.58
- Analyst Decision
- ARVN Strong Buy
- BEAM Buy
- Analyst Count
- ARVN 13
- BEAM 11
- Target Price
- ARVN $61.08
- BEAM $45.90
- AVG Volume (30 Days)
- ARVN 718.1K
- BEAM 1.3M
- Earning Date
- ARVN 10-30-2024
- BEAM 11-05-2024
- Dividend Yield
- ARVN N/A
- BEAM N/A
- EPS Growth
- ARVN N/A
- BEAM N/A
- EPS
- ARVN N/A
- BEAM N/A
- Revenue
- ARVN $161,100,000.00
- BEAM $349,643,000.00
- Revenue This Year
- ARVN $237.44
- BEAM N/A
- Revenue Next Year
- ARVN N/A
- BEAM $6.04
- P/E Ratio
- ARVN N/A
- BEAM N/A
- Revenue Growth
- ARVN 1.07
- BEAM 328.73
- 52 Week Low
- ARVN $21.17
- BEAM $20.84
- 52 Week High
- ARVN $53.08
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- ARVN 48.81
- BEAM 45.28
- Support Level
- ARVN $21.17
- BEAM $23.67
- Resistance Level
- ARVN $28.70
- BEAM $25.87
- Average True Range (ATR)
- ARVN 1.72
- BEAM 2.23
- MACD
- ARVN -0.41
- BEAM -0.24
- Stochastic Oscillator
- ARVN 51.44
- BEAM 19.58
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.